[Click eStock] "QuantaMatrix, Global Leader in Sepsis Diagnostics...Momentum for Expansion into 30 Overseas Markets"

On October 22, independent research firm ValueFinder analyzed that QuantaMatrix is the first Korean bio company to receive support from the U.S. government’s CARB-X program, and is expected to gain momentum for global expansion by leading the international sepsis diagnostics market and advancing into 30 overseas countries.

QuantaMatrix, which was listed on the KOSDAQ market in 2020, is a manufacturer of rapid antibiotic susceptibility testing products. It is recognized for having the world’s fastest antibiotic susceptibility test and became the first Korean diagnostics company to have its research published in the journal Nature.

Lee Chungheon, a researcher at ValueFinder, stated, “Domestically, QuantaMatrix is carrying out national projects led by the Ministry of Trade, Industry and Energy, and internationally, it has been selected as a recipient of the U.S. government-backed global partnership CARB-X, thereby proving its technological capabilities through both domestic and international government support.” He added, “In addition, the company is diversifying its business by launching Alzheimer’s early diagnostic equipment, Alzplus.”

Sepsis is known as a fatal disease with the highest direct mortality rate, where the survival rate decreases by 7 to 9 percent with each passing hour. Since it takes at least three days to identify a targeted antibiotic, the golden time is often missed, resulting in 50 million infections and 11 million deaths worldwide each year. The company’s rapid antibiotic susceptibility testing device, dRAST, can deliver results within 24 hours, which is a major advantage. In Korea, it has been listed on the national health insurance system as a selective benefit, and the company has reportedly signed distributor agreements in 30 countries worldwide, mainly in Europe.

Recognized for its technology, QuantaMatrix became the first Korean company to be selected as a recipient of the U.S. government-supported global partnership CARB-X. CARB-X is a global funding network under the U.S. Department of Health and Human Services that includes the Gates Foundation, and supports the development of commercialization strategies for products. QuantaMatrix is expected to receive support covering 50 to 70 percent of research and development costs, up to a maximum of 20 billion won, as it undertakes the task of developing a sepsis diagnostics platform.

Researcher Lee added, “In addition, the company is developing the uRAST device, which integrates blood culture and identification processes in a single step, with the goal of launching it within three years.”